USFDA revokes VAI Status of Aurobindo Pharma’s Unit IV

24 Feb 2020 Evaluate

The US Food and Drug Administration (USFDA) has revoked Voluntary Action Initiated (VAI) Status of Aurobindo Pharma’s Unit IV, a general injectable formulation manufacturing facility. The company has received a communication that the inspection conducted by the USFDA at its aforesaid Unit IV, from November 4,2019 to November 13, 2019, is still open and under review.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×